Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tjalf Ziemssen, Natalia Ashtamker, Svetlana Rubinchick, Volker Knappertz & Giancarlo Comi. (2017) Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opinion on Drug Safety 16:2, pages 247-255.
Read now
Read now
Catalina Coclitu, Cris S. Constantinescu & Radu Tanasescu. (2016) The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics 16:12, pages 1341-1356.
Read now
Read now
Articles from other publishers (30)
Nikan Amirkhani, Amirmohammad Khalaji, Parsa Alehossein, Masoomeh Safaei, Najme Aletaha & Arash Miroliaee. (2023) Drug‐induced liver injury by glatiramer acetate leading to liver transplant: A case report. JGH Open.
Crossref
Crossref
Xiaohong Ma, Rong Ma, Mengzhe Zhang, Baicheng Qian, Baoliang Wang & Weijing Yang. (2023) Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets. Pharmaceutics 15:3, pages 728.
Crossref
Crossref
Ümmügülsüm Koc, Steffen Haupeltshofer, Katharina Klöster, Seray Demir, Ralf Gold & Simon Faissner. (2023) Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis. Cells 12:4, pages 542.
Crossref
Crossref
. 2022. Multiple Sklerose. Multiple Sklerose
468
512
.
Lixiang Wang & Xin Wei. (2021) T Cell-Mediated Autoimmunity in Glaucoma Neurodegeneration. Frontiers in Immunology 12.
Crossref
Crossref
María José Zarzuelo-Romero, Cristina Pérez-Ramírez, Yasmín Cura, María Isabel Carrasco-Campos, Luciana María Marangoni-Iglecias, María Carmen Ramírez-Tortosa & Alberto Jiménez-Morales. (2021) Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients. Journal of Personalized Medicine 11:10, pages 1032.
Crossref
Crossref
Peter Rieckmann, Robert Zivadinov, Alexey Boyko, Krzysztof Selmaj, Jessica K. Alexander, Shaul Kadosh, Svetlana Rubinchick, Emily Bernstein-Hanlon, Yafit Stark, Natalia Ashtamker, Mat D. Davis & Omar Khan. (2021) Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7:4, pages 205521732110615.
Crossref
Crossref
María José Zarzuelo Romero, Cristina Pérez Ramírez, María Isabel Carrasco Campos, Almudena Sánchez Martín, Miguel Ángel Calleja Hernández, María Carmen Ramírez Tortosa & Alberto Jiménez Morales. (2021) Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis. Journal of Personalized Medicine 11:5, pages 335.
Crossref
Crossref
Aristides A. Capizzano, Toshio Moritani & Andrew Romeo. 2021. Diffusion-Weighted MR Imaging of the Brain, Head and Neck, and Spine. Diffusion-Weighted MR Imaging of the Brain, Head and Neck, and Spine
313
351
.
Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli & Claudio Gobbi. (2019) Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. BMC Neurology 19:1.
Crossref
Crossref
Sandra M. Skovdal, Stig Hill Christiansen, Karen Singers Johansen, Ole Viborg, Niels Henrik Bruun, Søren Jensen-Fangel, Ida Elisabeth Holm, Thomas Vorup-Jensen & Eskild Petersen. (2019) Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs. PLOS ONE 14:10, pages e0223647.
Crossref
Crossref
G Giovannoni, PA Brex, D Dhiraj, J Fullarton, M Freddi, B Rodgers-Gray & K Schmierer. (2019) Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. Multiple Sclerosis Journal - Experimental, Translational and Clinical 5:4, pages 205521731989310.
Crossref
Crossref
Елена ИвашковаElena Ivashkova, Марина ВотинцеваMarina Votinceva, Андрей ПетровAndrey Petrov, Игорь СтоляровIgor' Stolyarov. (2019) Ethical, clinical and scientific aspects of a research of medicinal drugs that alter progress of a multiple sclerosis at the current staging point. Vestnik Roszdravnadzora 2019:3, pages 63-69.
Crossref
Crossref
Olga Zapletalová. (2019) Multiple sclerosis - maternity and breastfeeding. Neurologie pro praxi 20:1, pages 33-36.
Crossref
Crossref
Edward J. FoxGuy J. BuckleBarry SingerVibhuti SinghAaron Boster. (2019) Lymphopenia and DMTs for relapsing forms of MS. Neurology Clinical Practice 9:1, pages 53-63.
Crossref
Crossref
Mehrdad Gholamzad, Masoumeh Ebtekar, Mehdi Shafiee Ardestani, Maryam Azimi, Zeinab Mahmodi, Mohammad Javad Mousavi & Saeed Aslani. (2018) A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflammation Research 68:1, pages 25-38.
Crossref
Crossref
Floriana De Angelis, Nevin A John & Wallace J Brownlee. (2018) Disease-modifying therapies for multiple sclerosis. BMJ, pages k4674.
Crossref
Crossref
Caila Vaughn, Aisha Bushra, Channa Kolb & Bianca Weinstock-Guttman. (2018) An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs 32:2, pages 161-178.
Crossref
Crossref
Magnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, Bianca Weinstock-Guttman, Judith Haas, Guillermo Izquierdo, Claire Riley, Amy Perrin Ross, Peleg Baruch, Talya Drillman & Patricia K. Coyle. (2018) Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. International Journal of MS Care 20:1, pages 9-14.
Crossref
Crossref
. 2018. Multiple Sklerose. Multiple Sklerose
261
352
.
Colin J. Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, Iris Grossman & Michael R. Hayden. (2017) A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Medicine 9:1.
Crossref
Crossref
Stig Hill Christiansen, Ronan A. Murphy, Kristian Juul-Madsen, Marlene Fredborg, Michael Lykke Hvam, Esben Axelgaard, Sandra M. Skovdal, Rikke Louise Meyer, Uffe B. Skov Sørensen, Arne Möller, Jens Randel Nyengaard, Niels Nørskov-Lauritsen, Mikala Wang, Mihaela Gadjeva, Kenneth A. Howard, Jane C. Davies, Eskild Petersen & Thomas Vorup-Jensen. (2017) The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Scientific Reports 7:1.
Crossref
Crossref
Kahina Amrouche & Christophe Jamin. (2017) Influence of drug molecules on regulatory B cells. Clinical Immunology 184, pages 1-10.
Crossref
Crossref
Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen, Masami Tanaka, Toshiro Miura & Volker Knappertz. (2017) Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis. Clinical and Experimental Neuroimmunology 8:2, pages 129-137.
Crossref
Crossref
Mat D. DavisNatalia AshtamkerJoshua R. SteinermanVolker Knappertz. (2017) Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. Neurology Neuroimmunology & Neuroinflammation 4:2.
Crossref
Crossref
Andreea Nissenkorn, Mona Kidon & Bruria Ben-Zeev. (2017) A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome. Pediatric Neurology 68, pages 40-43.
Crossref
Crossref
A. N. Boyko & V. M. Alifirova. (2017) Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 117:11, pages 135.
Crossref
Crossref
Victoria Galán Sánchez-Seco, Ignacio Casanova-Peño, Roberto Álvarez-Lafuente, Mónica Sánchez-Jiménez, Ángel García-Martínez, María Inmaculada Domínguez-Mozo, Ana María Arias-Leal, Marta García-Montojo & Rafael Arroyo-González. (2017) Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid. Clinical Neuropharmacology 40:1, pages 29-33.
Crossref
Crossref
Olga Zapletalová. (2016) Glatiramer acetate: long-term immunomodulatory therapy in multiple sclerosis - safety, efficacy,. Neurologie pro praxi 17:2, pages 95-99.
Crossref
Crossref
Kazumasa Yokoyama & Nobutaka Hattori. (2016) Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis. Folia Pharmacologica Japonica 148:2, pages 105-120.
Crossref
Crossref